BiomX Inc.

BiomX Inc. (ticker: PHGE) is a clinical-stage biopharmaceutical company focused on the discovery and development of phage therapies designed to selectively target and destroy bacteria linked to chronic diseases, including inflammatory skin conditions and liver disease. The company went public in 2019 through a merger with Chardan Healthcare Acquisitions Corp, a special purpose acquisition company sponsored by Chardan Capital Markets, and subsequently listed on the NYSE American exchange. The December 31, 2019 S-1/A amendment to its registration statement reflects the regulatory filings associated with that transaction. BiomX operates in the biotechnology and life sciences sector, with research programs spanning both acne-related dermatology and primary sclerosing cholangitis. For complete filing history, deal terms, and sponsor data on BiomX and hundreds of other SPAC transactions, sign up for full access at SpacDesk.